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Problem statement
The effect of pharmaceutical reimbursement policies on
innovation is of interest to policymakers aiming to ensure
access to effective medicines and contain costs while supporting development of effective new treatments for
unmet health needs. Yet the ways in which reimbursement
policies affect incentives to innovate are not well
understood.
Objectives
To assist policymakers in evaluating the impact of current
and prospective new policies, we developed a framework
for analyzing the impact of pharmaceutical reimbursement
policies on incentives to innovate.
Methods
The authors reviewed the research literature to identify
hypothetical channels through which policies stand to
influence the incentive to invest in development of innovative pharmaceutical products, and then developed a
conceptual model illustrating direct and indirect channels
of influence.
Results
We developed an analytical framework with which to
explore the link between reimbursement and investment
in research and development (R&D) yielding incremental,
substantial, and radical innovations, as well as in novel
products that do not offer new therapeutic advantages
over existing treatments.

This framework posits that there are three ways that
reimbursement policies and practices can affect an innovator’s expected return on investment (EROI) directly. The
first is by establishing a particular payment level, which in
turn affects average sales price in line with the share of the
prospective market represented by the payer. The second
is by setting a volume of sales at that payment level, as
may occur in the case of competitive bidding, for example.
The third is by influencing seller costs associated with
development, manufacture, or sale.
Reimbursement policies also stand to influence EROI
indirectly by establishing different incentives for key
actors. These incentives, in turn, affect effective price,
volume and, in some cases, seller costs.

Conclusions
While researchers have investigated the links between
EROI, ROI, and R&D in the pharmaceutical industry,
there is no empirical evidence to directly connect ROI
with innovation. Establishing such a connection would
entail looking at technical questions such as the ability
of potential innovators to achieve targeted research
outcomes.
Lessons learned and success factors
Validation of our conceptual model and analytical framework will require further research. Furthermore,
application of the framework is limited by the availability
of data by which to assess the impact on key outcomes.
Nevertheless, the framework can be helpful to policymakers faced with making timely decisions about adoption of new policies in the face of incomplete evidence.
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